Study Identifies Genetic Anomaly Associated With Poor Response to Common Asthma Treatment
A HSD3B1 genotype identifies glucocorticoid responsiveness in patients with severe asthma, according to a study published in the Proceedings of the National Academy of Sciences.
“Glucocorticoids, which modulate systemic inflammatory response, are commonly prescribed to treat severe asthma; however, until now we have not understood why many patients do not benefit from them,” said Nima Sharifi, MD, the Cleveland Clinic, Cleveland, Ohio. “These findings make the case for genetic testing and personalised treatment and provide important information for identifying which patients should be treated using different therapies.”
For the study, the researchers retrospectively analysed the association between patient genomes and lung function in more than 500 patients with asthma who received daily oral glucocorticoids treatment or no glucocorticoids treatment.
They found that a change to the gene HSD3B1, specifically the HSD3B1(1245A) variant, is associated with poor lung function and glucocorticoid treatment resistance. The analysis revealed that among patients receiving glucocorticoids, those with the variant had poorer lung function than those who did not have the genetic anomaly, suggesting that it contributes to resistance and helps drive the progression to severe asthma.
“Glucocorticoids, which modulate systemic inflammatory response, are commonly prescribed to treat severe asthma; however, until now we have not understood why many patients do not benefit from them,” said Nima Sharifi, MD, the Cleveland Clinic, Cleveland, Ohio. “These findings make the case for genetic testing and personalised treatment and provide important information for identifying which patients should be treated using different therapies.”
For the study, the researchers retrospectively analysed the association between patient genomes and lung function in more than 500 patients with asthma who received daily oral glucocorticoids treatment or no glucocorticoids treatment.
They found that a change to the gene HSD3B1, specifically the HSD3B1(1245A) variant, is associated with poor lung function and glucocorticoid treatment resistance. The analysis revealed that among patients receiving glucocorticoids, those with the variant had poorer lung function than those who did not have the genetic anomaly, suggesting that it contributes to resistance and helps drive the progression to severe asthma.
No comments:
Post a Comment